Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:2974-2978
Published online before print December 8, 2003, doi: 10.1161/01.CIR.0000106900.66354.30
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/24/2974    most recent
01.CIR.0000106900.66354.30v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zacharia, L. C.
Right arrow Articles by Dubey, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zacharia, L. C.
Right arrow Articles by Dubey, R. K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTRADIOL
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Other myocardial biology
Right arrow Remodeling
Right arrow Cardiovascular Pharmacology
Right arrow Pathophysiology
Right arrow Cell biology/structural biology
Right arrow Cell signalling/signal transduction
Right arrow Genetically altered mice
Right arrow Smooth muscle proliferation and differentiation
Right arrow Coronary circulation
Right arrow Receptor pharmacology
Right arrow Mechanism of atherosclerosis/growth factors

(Circulation. 2003;108:2974.)
© 2003 American Heart Association, Inc.


Brief Rapid Communications

Methoxyestradiols Mediate the Antimitogenic Effects of 17ß-Estradiol

Direct Evidence From Catechol-O-Methyltransferase–Knockout Mice

Lefteris C. Zacharia, PhD; Joseph A. Gogos, MD, PhD; Maria Karayiorgou, MD; Edwin K. Jackson, PhD; Delbert G. Gillespie, BS; Federica Barchiesi, PhD; Raghvendra K. Dubey, PhD

From the Center for Clinical Pharmacology, Departments of Medicine (L.C.Z., E.K.J., D.G.G., R.K.D.) and Pharmacology (E.K.J.), University of Pittsburgh, Pittsburgh, Pa; the Department of Obstetrics and Gynecology, University Hospital, Zurich, Switzerland (F.B., R.K.D.); and the Laboratory of Human Neurogenetics, Rockefeller University (M.K.), and Department of Physiology and Cellular Biophysics, Center for Neurobiology and Behavior, Columbia University (J.A.G.), New York, NY.

Correspondence to Dr Raghvendra K. Dubey, Clinic for Endocrinology (D217, NORD-1), University Hospital Zurich, Frauenklinikstrasse 10, 8091 Zurich, Switzerland. E-mail raghvendra.dubey{at}usz.ch

Received September 29, 2002; revision received October 27, 2003; accepted October 30, 2003.

Background— Studies using pharmacological agents suggest but do not prove that the antimitogenic effects of estradiol are caused by conversion of estradiol to hydroxyestradiols (mediated by CYP450s) followed by methylation of hydroxyestradiols to methoxyestradiols (mediated by catechol-O-methyltransferase, COMT).

Methods and Results— To test this hypothesis more rigorously, we used aortic smooth muscle cells (SMCs) from mice lacking COMT (COMT-KO). Wild-type (WT) but not COMT-KO SMCs efficiently converted 2-hydroxyestradiol to 2-methoxyestradiol. Both WT and COMT-KO SMCs expressed estrogen receptors. Estradiol and 2-hydroxyestradiol concentration-dependently inhibited serum-induced DNA synthesis, cell numbers, and collagen synthesis in WT but not COMT-KO SMCs. 2-Methoxyestradiol inhibited DNA synthesis, cell numbers, and collagen synthesis in both WT and COMT-KO SMCs.

Conclusions— These data provide strong evidence that the vascular antimitogenic effects of estradiol are estrogen receptor–independent and involve the sequential conversion of estradiol to hydroxyestradiols and then to methoxyestradiols.


Key Words: coronary disease • hormones • metabolism • muscle, smooth • receptors




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
V. M. Miller and S. P. Duckles
Vascular Actions of Estrogens: Functional Implications
Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, D. Wunder, B. Imthurn, and M. Rosselli
Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism
Hypertension, April 1, 2008; 51(4): 1197 - 1202.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
S. M. Salih, S. A. Salama, M. Jamaluddin, A. A. Fadl, L. J. Blok, C. W. Burger, M. Nagamani, and A. Al-Hendy
Progesterone-Mediated Regulation of Catechol-O-Methyl Transferase Expression in Endometrial Cancer Cells
Reproductive Sciences, February 1, 2008; 15(2): 210 - 220.
[Abstract] [PDF]


Home page
EndocrinologyHome page
R. K. Dubey, B. Imthurn, and E. K. Jackson
2-Methoxyestradiol: A Potential Treatment for Multiple Proliferative Disorders
Endocrinology, September 1, 2007; 148(9): 4125 - 4127.
[Full Text] [PDF]


Home page
EndocrinologyHome page
J. Bourghardt, G. Bergstrom, A. Krettek, S. Sjoberg, J. Boren, and A. Tivesten
The Endogenous Estradiol Metabolite 2-Methoxyestradiol Reduces Atherosclerotic Lesion Formation in Female Apolipoprotein E-Deficient Mice
Endocrinology, September 1, 2007; 148(9): 4128 - 4132.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
U. Eichenlaub-Ritter, U. Winterscheidt, E. Vogt, Y. Shen, H.-R. Tinneberg, and R. Sorensen
2-Methoxyestradiol Induces Spindle Aberrations, Chromosome Congression Failure, and Nondisjunction in Mouse Oocytes
Biol Reprod, May 1, 2007; 76(5): 784 - 793.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
S. A. Salama, A. B. Nasr, R. K. Dubey, and A. Al-Hendy
Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids
Reproductive Sciences, December 1, 2006; 13(8): 542 - 550.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Seli, O. Guzeloglu-Kayisli, H. Cakmak, U. A. Kayisli, B. Selam, and A. Arici
Estradiol Increases Apoptosis in Human Coronary Artery Endothelial Cells by Up-Regulating Fas and Fas Ligand Expression
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4995 - 5001.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. M. Masi, L. C. Hawkley, J. D. Berry, and J. T. Cacioppo
Estrogen Metabolites and Systolic Blood Pressure in a Population-Based Sample of Postmenopausal Women
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1015 - 1020.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Kappert, E. Caglayan, M. Huntgeburth, A. T. Baumer, J. Sparwel, M. Uebel, and S. Rosenkranz
17{beta}-Estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H538 - H546.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. K. Dubey, B. Imthurn, M. Barton, and E. K. Jackson
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
Cardiovasc Res, May 1, 2005; 66(2): 295 - 306.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Kisselev, W.-H. Schunck, I. Roots, and D. Schwarz
Association of CYP1A1 Polymorphisms with Differential Metabolic Activation of 17{beta}-Estradiol and Estrone
Cancer Res., April 1, 2005; 65(7): 2972 - 2978.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. K. Dubey, E. K. Jackson, D. G. Gillespie, M. Rosselli, F. Barchiesi, A. Krust, H. Keller, L. C. Zacharia, and B. Imthurn
Cytochromes 1A1/1B1- and Catechol-O-Methyltransferase-Derived Metabolites Mediate Estradiol-Induced Antimitogenesis in Human Cardiac Fibroblast
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 247 - 255.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson
Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here?
Hypertension, December 1, 2004; 44(6): 789 - 795.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, and B. Imthurn
Catecholamines Block the Antimitogenic Effect of Estradiol on Human Coronary Artery Smooth Muscle Cells
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3922 - 3931.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. C. Zacharia, C. A. Piche, R. M. Fielding, K. M. Holland, S. D. Allison, R. K. Dubey, and E. K. Jackson
2-Hydroxyestradiol Is a Prodrug of 2-Methoxyestradiol
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1093 - 1097.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Barchiesi, E. K. Jackson, B. Imthurn, J. Fingerle, D. G. Gillespie, and R. K. Dubey
Differential Regulation of Estrogen Receptor Subtypes {alpha} and {beta} in Human Aortic Smooth Muscle Cells by Oligonucleotides and Estradiol
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2373 - 2381.
[Abstract] [Full Text] [PDF]